ATL 101 - Telix Pharmaceuticals

Drug Profile

ATL 101 - Telix Pharmaceuticals

Alternative Names: 177Lu-J591; 90Y-J591; Anti-PSMA monoclonal antibody J591; huJ 591; J 591; Lu-177-J591; Lutetium-177-labelled anti-PSMA monoclonal antibody J591; MLN 591RL; MLN591; Monoclonal antibody J591; muJ591; Radiolabelled J591; Radiolabelled MLN591; TLX-591

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cornell University
  • Developer BZL Biologics; Weill Cornell Medical College
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease) in USA (IV)
  • 18 Jan 2017 Telix Pharmaceuticals and Atlab Pharma agree to co-develop ATL 101 for Prostate cancer
  • 18 Jan 2017 Atlab Pharma and Telix Pharmaceuticals plan a phase IIb trial for in Prostate cancer (Metastatic disease)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top